The use of animal-free reagents in the upstream manufacturing of biologic drugs is a common standard in biomanufacturing, essential for enhancing consistency and safety.
Recombinant Insulin has emerged as a key component in cell culture for biomanufacturing, improving a wide array of processes such as monoclonal antibody (mAb) production in CHO cells, virus production in various cell types, stem cell culture performance and production of viral vectors for gene therapy.
Another crucial element in cell-based vaccine production is trypsin, which is essential for virus expansion and activation of specific virus particles, notably in the case of influenza. However, the use of animal-derived trypsin carries the inherent risk of introducing adventitious contaminants, potentially leading to cell culture infection with serious consequences for both patients and production continuity.
The introduction of the enzyme TrypsiNNex® effectively addresses these safety and consistency concerns. As a high-purity, recombinantly produced, animal-free trypsin, the enzyme ensures a more robust production process, effectively reducing the risk of contamination.
Through a controlled production process, the enzyme maintains an inactive form until stabilization, which results in a high and consistent proportion of β-trypsin and makes it an ideal choice for virus-vaccine production, resulting in cost savings and improved efficiency.
In this webinar, the expert speakers will illustrate how both Recombinant Insulin and TrypsiNNex® significantly enhance the safety and efficiency of upstream biomanufacturing processes, thereby enhancing the overall efficiency of therapeutic biologics production. Furthermore, they will delve into how the implementation of reagents such as insulin plays a significant role in reducing overall upstream costs by increasing process efficiency.
Register for this webinar here to explore how innovative animal-free reagents are transforming upstream biomanufacturing.
The webinar is presented by Senior Product Manager Sara Bursomanno and Senior Product Manager Marie-Louise Lunn from Novo Nordisk Pharmatech and hosted by Xtalks.com.
